Share on facebook Share on Twitter Share on Google Plus Share This

Heart Failure

Heart failure happens when the heart cannot pump enough blood for the body.

Programs + Services


Clinical Nutrition

The Division of Clinical Nutrition at Tufts Medical Center provides inpatient and outpatient nutritional services.
More information about programs and services


Heart Failure + Cardiac Transplant Center

Tufts Medical Center's Heart Failure and Cardiac Transplant Center is a leader when it comes to heart transplantation. Learn more about the care provided.
More information about programs and services


Women's Heart Center

Discover The Women’s Heart Clinic at Tufts Medical Center and learn more about the cardiologists dedicated to providing women with the best heart care.
More information about programs and services

Doctors + Care Team

Marvin A. Konstam, MD

Marvin A. Konstam, MD

Title(s): Chief Physician Executive, The CardioVascular Center; Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-6293
Fax #: 617-636-7667

Heart failure, cardiac transplant

View Full Profile

James E. Udelson, MD

James E. Udelson, MD

Title(s): Chief, Division of Cardiology; Director, Nuclear Cardiology Laboratory; Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8066
Fax #: 617-636-7175

Cardiac imaging, heart failure

View Full Profile

Adel Ghuloom, MD

Adel Ghuloom, MD

Title(s): Director, Cardiovascular Critical Care Service
Department(s): Medicine, Cardiology, CardioVascular Center
Appt. Phone: 617-636-2273
Fax #:

Cardiovascular critical care

View Full Profile

Alan T. Kono, MD

Alan T. Kono, MD

Title(s): Cardiologist; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8068
Fax #: 617-636-6030

Heart failure

View Full Profile

Amanda Vest, MBBS, MPH

Amanda Vest, MBBS, MPH

Title(s): Associate Medical Director, Cardiac Transplantation Program; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8068
Fax #: 617-636-6030

Cardiology, heart failure, heart transplantation, mechanical circulatory support

View Full Profile

Ayan R. Patel, MD

Ayan R. Patel, MD

Title(s): Director, Cardiovascular Imaging and Hemodynamic Laboratory; Director, Women's Heart Center; Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-2273
Fax #: 617-636-8070

Echocardiography, heart failure, women's heart disease

View Full Profile

Daniel Levine, MD

Daniel Levine, MD

Title(s): Cardiologist
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8068
Fax #: 617-636-6030

Heart failure, coronary artery disease

View Full Profile

David DeNofrio, MD

David DeNofrio, MD

Title(s): Director, Advanced Heart Failure Program; Associate Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8068
Fax #: 617-636-6030

Heart failure, cardiac transplantation

View Full Profile

David M. Venesy, MD

David M. Venesy, MD

Title(s): Cardiologist; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8068
Fax #: 617-636-7175

Heart failure

View Full Profile

Frederick  Y. Chen, MD, PhD

Frederick Y. Chen, MD, PhD

Title(s): Chief, Cardiac Surgery; Professor of Surgery, Tufts University School of Medicine
Department(s): Surgery, CardioVascular Center, Cardiac Surgery
Appt. Phone: 617-636-5590
Fax #: 617-636-6410

Surgical treatment of acquired heart disease, surgical repair of valvular heart disease, minimally invasive surgery, arrhythmia surgery, heart transplantation, circulatory assist devices, hypertrophic cardiomyopathy (HCM)

View Full Profile

Hassan Rastegar, MD

Hassan Rastegar, MD

Title(s): Senior Cardiothoracic Surgeon; Professor, Tufts University School of Medicine
Department(s): Surgery, CardioVascular Center, Cardiac Surgery
Appt. Phone: 617-636-5590
Fax #: 617-636-6410

Surgical treatment of acquired heart disease, surgical repair of valvular heart disease, surgical repair of hypertrophic cardiomyopathy, minimally invasive surgery, arrhythmia surgery, heart transplantation, circulatory assist devices

View Full Profile

Kenneth G. Warner, MD

Kenneth G. Warner, MD

Title(s): Senior Cardiothoracic Surgeon; Associate Professor, Tufts University School of Medicine
Department(s): Surgery, CardioVascular Center, Cardiac Surgery
Appt. Phone: 617-636-5590
Fax #: 617-636-6410

Surgical management of adult and pediatric heart disease, heart transplantation

View Full Profile

Michael S. Kiernan, MD, MSc

Michael S. Kiernan, MD, MSc

Title(s): Director, Ventricular Assist Device Program; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8068
Fax #: 617-636-6030

Heart failure, cardiac transplantation, ventricular assist devices

View Full Profile

Navin K. Kapur, MD, FAHA, FACC, FSCAI

Navin K. Kapur, MD, FAHA, FACC, FSCAI

Title(s): Executive Director, The CardioVascular Center for Research and Innovation (CVCRI); Director, Acute Mechanical Circulatory Support Program; Director, Interventional Research Laboratories; Investigator, Molecular Cardiology Research Institute (MCRI); Associate Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8252
Fax #: 617-636-5913

Interventional cardiology, advanced heart failure, mechanical circulatory support

View Full Profile

Nicole M Orr, MD, FACC

Nicole M Orr, MD, FACC

Title(s): Cardiologist; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 781-762-0009
Fax #: 781-255-8880

Geriatric cardiology, echocardiography

View Full Profile

Robb Kociol, MD

Robb Kociol, MD

Title(s): Cardiologist
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8068
Fax #: 617-636-6030

Advanced heart failure, cardiac transplant, mechanical circulation support

View Full Profile

Research + Clinical Trials


A Study of a Technology-enabled Disease Management Program to Reduce Hospitalizations for Heart Failure (SpanCHFIII)

This study will randomize participants with a diagnosis of congestive heart failure and at least one risk factor for hospitalization to either a tablet computer and web based disease management program or a telephone based disease management program. Both interventions are home based with heart failure education and symptom monitoring provided by nurse managers. The nurse managers are in close communication with both the participants and the participants' physicians . The components of the disease management program have been developed at Tufts Medical Center and the New England Quality Care Alliance with studies showing improved clinical outcomes, including reduced hospitalizations. The goal of this study is to transition this successful home monitoring and disease management program to a table computer and web-based implementation to both improve clinical outcomes (reducing hospitalizations and improving self-perceived health status) and improve provider-patient satisfaction. We hypothesize that the tablet computer based disease management will decrease heart failure hospitalizations.
More information about research and clinical trials


Mechanical Circulatory Support: Measures of Adjustment and Quality of Life

The purpose of this study is to develop a measurement system to assess adjustment to mechanical circulatory support (MCS) (also referred to as a ventricular assist device [VAD]) and health-related quality of life (HRQOL) in patients with advanced heart failure who receive a VAD. The investigators refer to this measurement system as Mechanical Circulatory Support: Adjustment and Quality of Life (MCS A-QOL).
More information about research and clinical trials


A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)

This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with heart failure reduced ejection fraction (HFrEF). The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF.
More information about research and clinical trials


Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure: a randomized trial  (TAVR UNLOAD)

The TAVR UNLOAD trial is an international, multi-center, randomized, open-label, clinical trial comparing the safety and efficacy of Transcatheter Aortic Valve Replacement (TAVR) with the SAPIEN 3 Valve and optimized heart failure therapy ( OHFT ) versus OHFT in heart failure (HF) patients, with moderate aortic stenosis ( AS). OHFT is defined as guideline-directed medical therapy. It can be medication only or a combination of medical therapy and approved HF devices.

Clinical efficacy of TAVR is assessed after 1 year of follow-up in all 600 patients. All patients are followed for 2 years to evaluate the value of the study device in to treat patients with Heart Failure (HF) who have moderate aortic stenosis (AS). The Edwards SAPIEN 3 Valve has already been approved by the FDA for use in patients who require an aortic valve replacement due to severe aortic stenosis


More information about research and clinical trials


How Does Body Composition Change after Placement of a Left Ventricular Assist Device in Advanced Systolic Heart Failure?

Many patients with advanced heart failure describe loss of muscle mass and strength in their arms and legs. This process is known as ‘sarcopenia’ and has not been well studied in heart failure. In particular it is unknown whether the sarcopenia process can reverse after a heart failure patient receives a left ventricular assist device (LVAD, a surgically implanted heart pumpt). Therefore we are partnering with experts in nutrition and body composition at Tufts University to study changes in muscle mass, physical activity, food intake and metabolism in patients receiving an LVAD. Muscle mass is measured by two methods in the study, to help us determine which is the most accurate in heart failure patients: a dual-energy x-ray absorptiometry (DXA) scan and a non-radioactive isotope dilution technique. There are 3 study visits which each take a maximum of 4 hours, performed around the time of LVAD implant (30 days before to 21 days after), and at 3 months and 6 months after LVAD implantation.
More information about research and clinical trials


The Global cVAD Registry Protocol

The global cVAD registry collects clinical and procedural data retrospectively from hospital medical records for patients who received one or multiple Impella devices during routine clinical care. Patients who qualify for this registry include patients who received the Impella 2.5, Impella CP, or Impella 5.0 for left ventricular support as well as the Impella RP for right ventricular support during their inpatient stay. The registry is an observational, multicenter, retrospective records review. In order to best represent real-world practice, patients receiving Impella devices will be included in the registry without pre-selection. The purpose of the registry is to capture data that reflects "real world"? use of the Implella devices in clinical practice and provide insight into patients characteristics, comorbid conditions, patterns of care, quality of care and performance measurements.
More information about research and clinical trials


Entrestotm (LCZ696) In Advanced Heart Failure (LIFE Study) (HFN-LIFE)

The purpose of this study is to test whether EntrestoTM, a newly approved drug for heart failure that combines sacubitril and valsartan, improves symptoms and outcomes in persons with advanced heart failure in comparison to treatment with valsartan alone over 24 weeks. EntrestoTM has been studied in only a very small number of patients with advanced heart failure, like you. This study is beind done to obtain more information on the benefits and risks of EntrestoTM in patients with advanced heart failure. Both EntrestoTM and valsartan have previously been approved by the U.S. Food and Drug Administration (FDA)for people with heart failurea nd are available by prescription from a licensed medical doctor. Currently EntrestoTM is only available under the brand name EntrestoTM, there is no generic form of EntrestoTM. You do not have to take part in this study in order to receive EntrestoTM.
More information about research and clinical trials


A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF).

This is a prospective, multicenter, phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure (HF) with preserved Ejection Fraction (HFpEF). The objective of this event-driven trial is to demonstrate superiority of empagliflozin 10 mg versus placebo in patients with symptomatic, chronic HF and preserved ejection fraction (LVEF > 40%) under stable treatment of HF symptoms. Empagliflozin is an orally available, potent, and selective inhibitor of the renal SGLT-2. Its selective inhibition reduces renal reabsorption of sodium and glucose. This leads to both increased urinary sodium and glucose excretion. While the urinary sodium excretion returns to normal within few days of empagliflozin administration, the effect on urinary glucose continues. The study treatment period will run for approximately 20- 38 months, until the required number of adjudicated primary events are reached. In Addition to the treatment period there is a 4-21 day screening period and a 30 day follow up visit.
More information about research and clinical trials


A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF).

This is a prospective, multicenter, phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure (HF) with reduced Ejection Fraction (HFrEF). The objective of this event-driven trial is to demonstrate superiority of empagliflozin 10 mg versus placebo in patients with symptomatic, chronic HF and preserved ejection fraction (LVEF ≤40%) under stable treatment of HF symptoms. Empagliflozin is an orally available, potent, and selective inhibitor of the renal SGLT-2. Its selective inhibition reduces renal reabsorption of sodium and glucose. This leads to both increased urinary sodium and glucose excretion. While the urinary sodium excretion returns to normal within few days of empagliflozin administration, the effect on urinary glucose continues. The study treatment period will run for approximately 20- 38 months, until the required number of adjudicated primary events are reached. In Addition to the treatment period there is a 4-21 day screening period and a 30 day follow up visit.
More information about research and clinical trials


Prospective Hemodynamic Assessment of Cardica Resynchronization Therapy Effectiveness Following Left Ventricular Assist Device Support

To understated the effects of different pacemaker settings on heart function in patients with LVADS.
More information about research and clinical trials


A study to evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure

This is a research study to investigate the effectiveness and safety of a device for patients with heart failure with preserved ejection fraction (HFpEF). Patients with a left ventricular ejection fraction greater than or equal to 40%, symptoms of heart failure and elevated filling pressures on a test called a right heart catheterization may be eligible to enroll. Participation in this multicenter study involves being randomly assigned either to implantation of an Inter Atrial Shunt Device (IASD) System II, or a sham procedure. Participants will be followed by the Tufts Heart Failure Research Team at regular intervals, for a total of 5 years; however they will remain under the care of their usual Cardiologist. The IASD System II consists of a self-expanding metal structure that is placed into the wall between the upper chambers of the heart (right and left atria) to enable blood to move between these chambers. For HFpEF patients with high pressures in the left atrium, it is thought that enabling blood to move from the left atrium into the right atrium could improve symptoms such as shortness of breath. This device is not yet approved in the United States. Please look at the study website for more information (www.treatmyheartfailure.com).
More information about research and clinical trials


Subcutaneous Furosemide in Acute Decompensated Heart Failure

The purpose of this study is to test if sending you home early from the hospital with a furosemide pump will improve your outcome after a heart failure admission. An investigational pump and drug combination - the sc2WearPump and Furosemide Injection Solution (SCP-101, made scPharmaceuticals), will be used to provide you with the drug you need and the study will also determine if this combination product is safe. "Investigational" means that the combination pump/drug is currently being tested in research studies and is not approved by the US Food and Drug Administration (FDA) for standard medical use. Furosemide is already approved by the FDA for the treatment of heart failure, but tihs study will test a furosemide injection given under the skin using a pump (sc2Wear Pump) applied to the belly.
More information about research and clinical trials


Dilated Cardiomyopathy Precision Medicine Study

The purpose of this study is to identify gene changes that cause DCM and gene differences that influence the development and severity of DCM. The genetic screening done for this study will be returned to the subject. These genetic studies may identify a change in a gene that has already been linked with DCM, a change in a gene not previously associated with DCM, or these studies may identify a gene or genes that affect the development and severity of the DCM. With this knowledge we hope to have a better understanding of how genes and gene changes cause DCM. We are collaborating with Dr. Ray Hershberger from The Ohio State University in the Dilated Cardiomyopathy (DCM) Precision Medicine Study, a family-based study aimed at enrolling individuals of European or African ancestry, and identifying the genes responsible for idiopathic DCM. Ours is one of several sites forming part of the DCM Consortium, a multi-institutional group established to conduct DCM research. This study requires one in person visit and a 10-15 minute phone call annually.
More information about research and clinical trials


Characterizing HIV-related Diastolic Dysfunction

This is a multicenter clinical trial of a cross section of HIV+ patients with and without diastolic dysfunction. Approximately 200 HAART-treated virally suppressed HIV+ subjects (100 HIV+/DD+ & 100 HIV+/DD-) will be enrolled. Currently only accepted patients who have HIV and Diastolic Dysfunction. This study will evaluate biomarkers, phenomapping, metabolomics, cMRI, and echocardiography to determined characteristics unique to this patient population.
More information about research and clinical trials

Tufts Medical Center and Floating Hospital for Children have high quality care.

Quality + Safety

A world-class teaching hospital shouldn’t make you feel small.  At Tufts Medical Center the patient is at the center of everything that we do.  This means we’re committed to providing the highest quality of care in a safe, friendly environment.

Learn more
The City of Boston shows the harbor and buildings

200 Years of Caring for the Community

Tufts Medical Center has been taking care of Boston and the surrounding community for more than 200 years.

Read about our enduring history